Medical and Pharmaceutical Freenome gets FDA breakthrough designation for ‘SimpleScreen’ lung cancer blood test Achievement builds on firm securing agency's approval for a colorectal cancer test variation Rowan DunneAugust 13, 2026
Medical and Pharmaceutical FDA panel to review GRAIL’s Galleri multi-cancer blood test in September The application contains results from more than 70,000 participants enrolled in the intervention arm of the NHS-Galleri trial Joseph MortonAugust 11, 2026
AI and Autonomy Robotic lung biopsy system brings earlier cancer detection closer to patients Lung cancer remains the leading cause of cancer deaths worldwide Joseph MortonJuly 15, 2026
Medical and Pharmaceutical Canadian trial to test blood-based cancer detection in 7,000 survivors SHERLOCK will recruit patients who have already undergone treatments intended to cure their disease Joseph MortonJuly 14, 2026
Medical and Pharmaceutical Emerging biomarkers may improve early colorectal cancer detection and treatment monitoring Colonoscopy remains the gold standard for detecting colorectal cancer Joseph MortonJuly 6, 2026
Medical and Pharmaceutical University of Manitoba researchers develop dual-mode breast cancer imaging system The system uses wave imaging to look inside breast tissue Joseph MortonMay 7, 2026
AI and Autonomy AI-designed drugs near human trials as AlphaFold enters clinical phase Isomorphic Labs launched in 2021 as a unit of Alphabet Inc Joseph MortonApril 29, 2026
Medical and Pharmaceutical New blood test approach could detect multiple cancers earlier, researchers say Scientists have long sought easier ways to identify cancer sooner Joseph MortonApril 27, 2026
Medical and Pharmaceutical Guardant Health launches multi-cancer blood test in Asia through Manulife partnership Cancer remains a leading cause of death across Asia, driving demand for early screening tools Joseph MortonMarch 18, 2026
Medical and Pharmaceutical GRAIL plunges hard after ‘Galleri’ multi-cancer test fails to meet primary endpoint The slide comes in tandem with financial results that beat expectations Rowan DunneFebruary 20, 2026